Medtronic (MDT) said Wednesday that the US Food and Drug Administration has cleared its new InPen app, which features missed meal dose detection, enabling its Smart MDI system launch with the Simplera continuous glucose monitor, or CGM.
The device maker said it will begin a limited market release with existing standalone CGM and InPen customers, followed by a broader commercial launch.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments